scholarly journals An Integrated Multi-Sensor Approach for the Remote Monitoring of Parkinson’s Disease

Sensors ◽  
2019 ◽  
Vol 19 (21) ◽  
pp. 4764 ◽  
Author(s):  
Giovanni Albani ◽  
Claudia Ferraris ◽  
Roberto Nerino ◽  
Antonio Chimienti ◽  
Giuseppe Pettiti ◽  
...  

The increment of the prevalence of neurological diseases due to the trend in population aging demands for new strategies in disease management. In Parkinson’s disease (PD), these strategies should aim at improving diagnosis accuracy and frequency of the clinical follow-up by means of decentralized cost-effective solutions. In this context, a system suitable for the remote monitoring of PD subjects is presented. It consists of the integration of two approaches investigated in our previous works, each one appropriate for the movement analysis of specific parts of the body: low-cost optical devices for the upper limbs and wearable sensors for the lower ones. The system performs the automated assessments of six motor tasks of the unified Parkinson’s disease rating scale, and it is equipped with a gesture-based human machine interface designed to facilitate the user interaction and the system management. The usability of the system has been evaluated by means of standard questionnaires, and the accuracy of the automated assessment has been verified experimentally. The results demonstrate that the proposed solution represents a substantial improvement in PD assessment respect to the former two approaches treated separately, and a new example of an accurate, feasible and cost-effective mean for the decentralized management of PD.

Sensors ◽  
2021 ◽  
Vol 21 (8) ◽  
pp. 2821
Author(s):  
Chariklia Chatzaki ◽  
Vasileios Skaramagkas ◽  
Nikolaos Tachos ◽  
Georgios Christodoulakis ◽  
Evangelia Maniadi ◽  
...  

Gait analysis is crucial for the detection and management of various neurological and musculoskeletal disorders. The identification of gait events is valuable for enhancing gait analysis, developing accurate monitoring systems, and evaluating treatments for pathological gait. The aim of this work is to introduce the Smart-Insole Dataset to be used for the development and evaluation of computational methods focusing on gait analysis. Towards this objective, temporal and spatial characteristics of gait have been estimated as the first insight of pathology. The Smart-Insole dataset includes data derived from pressure sensor insoles, while 29 participants (healthy adults, elderly, Parkinson’s disease patients) performed two different sets of tests: The Walk Straight and Turn test, and a modified version of the Timed Up and Go test. A neurologist specialized in movement disorders evaluated the performance of the participants by rating four items of the MDS-Unified Parkinson’s Disease Rating Scale. The annotation of the dataset was performed by a team of experienced computer scientists, manually and using a gait event detection algorithm. The results evidence the discrimination between the different groups, and the verification of established assumptions regarding gait characteristics of the elderly and patients suffering from Parkinson’s disease.


BMC Neurology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Sara Alberto ◽  
Sílvia Cabral ◽  
João Proença ◽  
Filipa Pona-Ferreira ◽  
Mariana Leitão ◽  
...  

Abstract Background Gait impairments are among the most common and impactful symptoms of Parkinson’s disease (PD). Recent technological advances aim to quantify these impairments using low-cost wearable systems for use in either supervised clinical consultations or long-term unsupervised monitoring of gait in ecological environments. However, very few of these wearable systems have been validated comparatively to a criterion of established validity. Objective We developed two movement analysis solutions (3D full-body kinematics based on inertial sensors, and a smartphone application) in which validity was assessed versus the optoelectronic criterion in a population of PD patients. Methods Nineteen subjects with PD (7 female) participated in the study (age: 62 ± 12.27 years; disease duration: 6.39 ± 3.70 years; HY: 2 ± 0.23). Each participant underwent a gait analysis whilst barefoot, at a self-selected speed, for a distance of 3 times 10 m in a straight line, assessed simultaneously with all three systems. Results Our results show excellent agreement between either solution and the optoelectronic criterion. Both systems differentiate between PD patients and healthy controls, and between PD patients in ON or OFF medication states (normal difference distributions pooled from published research in PD patients in ON and OFF states that included an age-matched healthy control group). Fair to high waveform similarity and mean absolute errors below the mean relative orientation accuracy of the equipment were found when comparing the angular kinematics between the full-body inertial sensor-based system and the optoelectronic criterion. Conclusions We conclude that the presented solutions produce accurate results and can capture clinically relevant parameters using commodity wearable sensors or a simple smartphone. This validation will hopefully enable the adoption of these systems for supervised and unsupervised gait analysis in clinical practice and clinical trials.


2021 ◽  
Author(s):  
Paulo Eduardo Lahoz Fernandez ◽  
Guilherme Diogo Silva ◽  
Eduardo Genaro Mutarelli

Background: Studies across subspecialties of neurology (SON) report noninferiority of telemedicine (TM) compared with face-to-face intervention (FTF-I). Clinical scales (CS) are important tools for outcome measures in clinical care. However, which CS in FTF-I can be used in teleneurology is unclear. Objectives: Define the most used CS in studies comparing TM with FTF-I in different SON. Design and Setting/Methods: We searched PubMed and Embase for randomized controlled trials, published from 2011 to April 2021, with Key words ‘’telemedicine’’ cross-referenced with ‘’neurology’’ or neurological diseases, considering the synonyms. Results: 43 eligible studies in 400 records, from 12 countries, with 5600 patients and 8 SON: stroke (10), headache (4), epilepsy (6), cognitive disorders (7), demyelinating diseases (8), movement disorders (3), neuromuscular diseases (3), and vestibular diseases (2). The most used CS: National Institute of Health Stroke Scale (NIHSS) and Modified Rankin Scale (MRS) for stroke impairment and limitation; Headache Impact Test (HIT-6) and Migraine Disability Assessment Scale (MIDAS) for headache disability; Quality Of Life in Epilepsy Inventory (QOL-31) for seizure burden; Mini-Mental State Exam (MMSE) and Zarit Burden Interview (ZBI) for cognitive function and caregiver burden in dementia care; Expanded Disability Status Scale (EDSS) and Fatigue Impact Scale (FIS) for disability and fatigue in Multiple Sclerosis; Parkinson’s disease Questionnaire (PDQ-39) and Unified Parkinson’s Disease Rating Scale (UPDRS) for QOL and disability in PD; Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) for severity in ALS; and Vertigo Symptom Scale Short form (VSS-SF) for vertigo. Conclusions: We present feasible CS usually applied in teleneurology that can be used as important tools for future findings in TM research and practice.


2009 ◽  
Vol 33 (1) ◽  
pp. 82-88 ◽  
Author(s):  
Kamiar Ghoseiri ◽  
Bijan Forogh ◽  
Mohammad Ali Sanjari ◽  
Ahlam Bavi

This paper explores the use of biofeedback to improve gait in Parkinson's disease (PD) and, in particular, reports on the design and testing of a new vibratory orthosis. The orthosis causes a rhythmic vibratory stimulus to be applied to one or other side of the lumbar region. The stimulus is synchronized with stepping through the use of heel-located switches; each switch controls the stimulus to the corresponding side of the body. In the experimental evaluation it was hypothesized that step-synchronized, vibratory stimulation applied to the lumbar region will lead to an increase in walking velocity in patients with idiopathic Parkinson's disease. Subjects were asked to carry out walking trials under two conditions. In one condition, the vibratory orthosis was active; in the other condition the vibratory orthosis was inactive. Walking velocity was measured over a straight, 10 m walkway. A comparison between the two conditions using a paired t-test showed a significant increase in walking velocity when the vibratory orthosis was active, compared with the inactive condition. It was speculated that use of the vibratory orthosis, which stimulates proprioceptive receptors, may lead to an improvement in gait, stability and may support gait re-education in PD patients. It was also suggested that the results may inform future ideas for rehabilitation of similar neurological diseases.


2018 ◽  
Vol 10 (3) ◽  
Author(s):  
Amir Hassan Habibi ◽  
Arezo Anamoradi ◽  
Gholam Ali Shahidi ◽  
Saeed Razmeh ◽  
Elham Alizadeh ◽  
...  

Dyskinesia refers to any involuntary movement, such as chorea, dystonia, ballism that affect any part of the body. Levodopa-induced dyskinesia is a neurological disorder that afflicts many patients with Parkinson disease usually 5 years after the onset of levodopa therapy and can cause severe disability. The pathophysiology of this dyskinesia is complex and not fully understood. However, the association between vitamin D and Parkinson disease is interesting. The present study was conducted to evaluate the effect of vitamin D on levodopa induced dyskinesia in patients with Parkinson’s disease .In this Double blind clinical trial, 120 patients with PD divided into two groups randomly, vitamin D and placebo group. A dose of 1000 IU/d was selected, Demographic information is registered. In the first visit, three variables have been measured which were the duration, severity of dyskinesia and unified Parkinson’s disease rating scale (UPDRS). These variables were measured again after 3 months and the data was analyzed using SPSS 22. There are no differences between two groups after 3 months. This study revealed, vitamin D has no effects on improvement of levodopa induced dyskinesia.


Author(s):  
Hamid Khodakarami ◽  
Navid Shokouhi ◽  
Malcolm Horne

Abstract Background Fluctuations in motor function in Parkinson’s Disease (PD) are frequent and cause significant disability. Frequently device assisted therapies are required to treat them. Currently, fluctuations are self-reported through diaries and history yet frequently people with PD do not accurately identify and report fluctuations. As the management of fluctuations and the outcomes of many clinical trials depend on accurately measuring fluctuations a means of objectively measuring time spent with bradykinesia or dyskinesia would be important. The aim of this study was to present a system that uses wearable sensors to measure the percentage of time that bradykinesia or dyskinesia scores are above a target as a means for assessing levels of treatment and fluctuations in PD. Methods Data in a database of 228 people with Parkinson’s Disease and 157 control subjects, who had worn the Parkinson’s Kinetigraph ((PKG, Global Kinetics Corporation™, Australia) and scores from the Unified Parkinson’s Disease Rating Scale (UPDRS) and other clinic scales were used. The PKG’s provided score for bradykinesia and dyskinesia every two minutes and these were compared to a previously established target range representing a UPDRS III score of 35. The proportion of these scores above target over the 6 days that the PKG was worn were used to derive the percent time in bradykinesia (PTB) and percent time in dyskinesia (PTD). As well, a previously describe algorithm for estimating the amplitude of the levodopa response was used to determine whether a subject was a fluctuator or non-fluctuator. Results Using this approach, a normal range of PTB and PTD based on Control subject was developed. The level of PTB and PTD experienced by people with PD was compared with their levels of fluctuation. There was a correlation (Pearson’s ρ = 0.4) between UPDRS II scores and PTB: the correlation between Parkinson Disease Questionnaire scores and UPDRS Total scores and PTB and slightly lower. PTB and PTD fell in response to treatment for bradykinesia or dyskinesia (respectively) with greater sensitivity than clinical scales. Conclusions This approach provides an objective assessment of the severity of fluctuations in Parkinson’s Disease that could be used in in clinical trials and routine care.


Sensors ◽  
2021 ◽  
Vol 21 (16) ◽  
pp. 5437
Author(s):  
Samuel Rupprechter ◽  
Gareth Morinan ◽  
Yuwei Peng ◽  
Thomas Foltynie ◽  
Krista Sibley ◽  
...  

Gait is a core motor function and is impaired in numerous neurological diseases, including Parkinson’s disease (PD). Treatment changes in PD are frequently driven by gait assessments in the clinic, commonly rated as part of the Movement Disorder Society (MDS) Unified PD Rating Scale (UPDRS) assessment (item 3.10). We proposed and evaluated a novel approach for estimating severity of gait impairment in Parkinson’s disease using a computer vision-based methodology. The system we developed can be used to obtain an estimate for a rating to catch potential errors, or to gain an initial rating in the absence of a trained clinician—for example, during remote home assessments. Videos (n=729) were collected as part of routine MDS-UPDRS gait assessments of Parkinson’s patients, and a deep learning library was used to extract body key-point coordinates for each frame. Data were recorded at five clinical sites using commercially available mobile phones or tablets, and had an associated severity rating from a trained clinician. Six features were calculated from time-series signals of the extracted key-points. These features characterized key aspects of the movement including speed (step frequency, estimated using a novel Gamma-Poisson Bayesian model), arm swing, postural control and smoothness (or roughness) of movement. An ordinal random forest classification model (with one class for each of the possible ratings) was trained and evaluated using 10-fold cross validation. Step frequency point estimates from the Bayesian model were highly correlated with manually labelled step frequencies of 606 video clips showing patients walking towards or away from the camera (Pearson’s r=0.80, p<0.001). Our classifier achieved a balanced accuracy of 50% (chance = 25%). Estimated UPDRS ratings were within one of the clinicians’ ratings in 95% of cases. There was a significant correlation between clinician labels and model estimates (Spearman’s ρ=0.52, p<0.001). We show how the interpretability of the feature values could be used by clinicians to support their decision-making and provide insight into the model’s objective UPDRS rating estimation. The severity of gait impairment in Parkinson’s disease can be estimated using a single patient video, recorded using a consumer mobile device and within standard clinical settings; i.e., videos were recorded in various hospital hallways and offices rather than gait laboratories. This approach can support clinicians during routine assessments by providing an objective rating (or second opinion), and has the potential to be used for remote home assessments, which would allow for more frequent monitoring.


2019 ◽  
Vol 2019 ◽  
pp. 1-9
Author(s):  
Kyohei Mikami ◽  
Makoto Shiraishi ◽  
Tsutomu Kamo

Background. We believe that, in patients with Parkinson’s disease (PD), a forward-directed increase in the subjective vertical position (SV) leads to prolonged worsening of forward flexion of the trunk (FFT) mainly because the body adjusts to the SV. We conducted a study to clarify the relation between the SV angle, FFT angle, and various other clinical measures by comparing baseline values against values obtained 1 year later. Methods. A total of 39 PD patients (mean age, 71.9 ± 10.1 years; disease duration, 7.2 ± 5.4 years; modified Hoehn & Yahr (mH&Y) score, 2.6 ± 0.7) were enrolled. The Unified Parkinson’s Disease Rating Scale score, Mini-Mental State Examination (MMSE) score, mH&Y score, FFT angle, SV angle, and levodopa-equivalent dose (LED) were assessed at the time of enrollment (baseline evaluation) and 1 year later. Results. Eighteen patients (46%) complied with the protocol and completed the study. Significant increases were observed in the 1-year SV angle (p=0.02), MMSE score (p=0.008), and LED (p=0.001) compared to baseline values. Correlation was observed between the baseline SV angle and baseline and 1-year FFT angles (r=0.64, p=0.008 and r=0.58, p=0.012, respectively) and between the 1-year SV angle and 1-year FFT angle (r=0.63, p=0.005). Conclusion. Our data suggest that the SV contributes to increased FFT.


Author(s):  
OJS Admin

Parkinson's disease is a neurodegenerative disease and no proper treatment or cure has been developed for it till now. Worldwide the incidence of disease has been increased with age. Latest researches have focused on the dietary aspects of Parkinson's and have revealed that a ketogenic diet may be benecial in prevention and for therapy. The main aim of this review article was to explore the dietary elements present in ketogenic diet and their respective roles in the body with link to Parkinson's disease. Ketogenic diet has been used in many neurological diseases due to its neuroprotective effects. Ketogenic diet is a normal caloric diet that composed of with high fat (mostly composed with polyunsaturated fatty acids), medium protein and low in carbohydrates. The composition of this diet makes body to utilize fatand ketones for energy by altering glucose. The major constituents present in a ketogenic diet which have neuroprotective effects against Parkinson's are; B complex vitamins, Omega-3 Fatty Acids, Omega-6 Fatty acids and Vitamin D. The benecial effects have been evaluated regarding the role of constituents present in a ketogenic diet on Parkinson's disease. The need for further researches, especially clinical trials forthe different constituents of ketogenic diet and their neuroprotective properties are still required.


2019 ◽  
Author(s):  
Jingying Wang ◽  
Dawei Gong ◽  
Huichun Luo ◽  
Wenbin Zhang ◽  
Lei Zhang ◽  
...  

BACKGROUND Gait impairments including shuffling gait and hesitation are common in people with Parkinson’s disease (PD), and have been linked to increased fall risk and freezing of gait. Nowadays the gait metrics mostly focus on the spatiotemporal characteristics of gait, but less is known of the angular characteristics of the gait, which may provide helpful information pertaining to the functional status and effects of the treatment in PD. OBJECTIVE This study aimed to quantify the angles of steps during walking, and explore if this novel step angle metric is associated with the severity of PD and the effects of the treatment including the acute levodopa challenge test (ALCT) and deep brain stimulation (DBS). METHODS A total of 18 participants with PD completed the walking test before and after the ALCT, and 25 participants with PD completed the test with the DBS on and off. The walking test was implemented under two conditions: walking normally at a preferred speed (single task) and walking while performing a cognitive serial subtraction task (dual task). A total of 17 age-matched participants without PD also completed this walking test. The angular velocity was measured using wearable sensors on each ankle, and three gait angular metrics were obtained, that is mean step angle, initial step angle, and last step angle. The conventional gait metrics (ie, step time and step number) were also calculated. RESULTS The results showed that compared to the control, the following three step angle metrics were significantly smaller in those with PD: mean step angle (<i>F</i><sub>1,48</sub>=69.75, <i>P</i>&lt;.001, partial eta-square=0.59), initial step angle (<i>F</i><sub>1,48</sub>=15.56, <i>P</i>&lt;.001, partial eta-square=0.25), and last step angle (<i>F</i><sub>1,48</sub>=61.99, <i>P</i>&lt;.001, partial eta-square=0.56). Within the PD cohort, both the ALCT and DBS induced greater mean step angles (ACLT: <i>F</i><sub>1,38</sub>=5.77, <i>P</i>=.02, partial eta-square=0.13; DBS: <i>F</i><sub>1,52</sub>=8.53, <i>P</i>=.005, partial eta-square=0.14) and last step angles (ACLT: <i>F</i><sub>1,38</sub>=10, <i>P</i>=.003, partial eta-square=0.21; DBS: <i>F</i><sub>1,52</sub>=4.96, <i>P</i>=.003, partial eta-square=0.09), but no significant changes were observed in step time and number after the treatments. Additionally, these step angles were correlated with the Unified Parkinson's Disease Rating Scale, Part III score: mean step angle (single task: <i>r</i>=–0.60, <i>P</i>&lt;.001; dual task: <i>r</i>=–0.52, <i>P</i>&lt;.001), initial step angle (single task: <i>r</i>=–0.35, <i>P</i>=.006; dual task: <i>r</i>=–0.35, <i>P</i>=.01), and last step angle (single task: <i>r</i>=–0.43, <i>P</i>=.001; dual task: <i>r</i>=–0.41, <i>P</i>=.002). CONCLUSIONS This pilot study demonstrated that the gait angular characteristics, as quantified by the step angles, were sensitive to the disease severity of PD and, more importantly, can capture the effects of treatments on the gait, while the traditional metrics cannot. This indicates that these metrics may serve as novel markers to help the assessment of gait in those with PD as well as the rehabilitation of this vulnerable cohort.


Sign in / Sign up

Export Citation Format

Share Document